Today, Celltrion announced that the FDA has issued Complete Response Letters (CRLs) for 2 of its products, CT-P10, a proposed rituximab biosimilar referencing Rituxan, and CT-P6, a proposed trastuzumab biosimilar referencing Herceptin.
Today, Celltrion announced that the FDA has issued Complete Response Letters (CRLs) for 2 of its products, CT-P10, a proposed rituximab biosimilar referencing Rituxan, and CT-P6, a proposed trastuzumab biosimilar referencing Herceptin.
According to a statement on Celltrion’s website, the FDA has requested supplementary information about the products. Celltrion says that it will work closely with regulators to address the issues that led to the CRLs, and that it expects to receive FDA approval of both drugs within the year.
US regulatory rejection of the 2 products does not come entirely as a surprise; the Republic of Korea drug maker received the FDA’s Form 483 last year, noting 12 observations related to a range of issues, including incomplete records, inappropriately designed equipment, deficient environmental monitoring, and inadequate validation of sterilization processes. Then, in February 2018, Celltrion received a warning letter from the agency related to its manufacturing processes. While Celltrion assured investors that it was making progress to address the concerns in a timely fashion, Celltrion’s partner Teva said that remediation of the manufacturing facility’s issues would likely result in a “delayed approval” of the drugs.
Despite these manufacturing issues at the Celltrion facility, CT-P6 recently gained an EU marketing authorization, and Celltrion plans to launch the product in Europe under the name Herzuma.
CT-P10 is also approved in the European Union, where the treatment is marketed under the brand names Blitzima, Ritemvia, Rituzena, and Truxima. Introduction of the partnership’s biosimilar (as well as Sandoz’s competing biosimilar product, Riximyo) in the European Union has begun to have a substantial impact on the market for rituximab; Roche said in its 2017 annual report to investors that European sales of innovator rituximab dropped by 11% because of competition from biosimilar challengers.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.